Everything below concerns RP-HPLC purity. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-29. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
| Property | Value | Notes |
|---|---|---|
| Route studied | Intranasal | Predominant route in published reports |
| Circulation stability | Short, minutes scale | Peptidases cleave it; the tail slows the process |
| Analytical method | RP-HPLC with mass spectrometry | Used for identity and purity assessment |
| Reported outcome domains | Anxiety and cognitive measures | Derived from small, mostly regional trials |
| Regulatory status | Marketed in Russia | Availability outside that market is limited |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Reversed-phase high-performance liquid chromatography is the standard technique for estimating peptide purity. The result is a peak-area percentage, which describes how much of the detected material elutes as the main peak in one run. Mass spectrometry confirms the molecular mass and can reveal truncated, adducted, or otherwise modified species. Amino acid analysis or tandem mass spectrometry can address sequence fidelity when identity is in doubt. None of these measurements, taken alone, establishes that a sample is fit for any specific purpose.
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
==== Academic licencing, licence steering and AI commercialisation ==== The use of academic research for Large Language Models (LLMs) has sparked debate within the Open Access movement. Academics accuse publishers of steering authors towards restrictive licences to retain exclusive commercial rights for AI training deals. In 2024, publishers like Taylor & Francis announced lucrative AI training partnerships, often without consulting authors. This dynamic complicates copyright litigation, as seen in the US when Elsevier sued Meta over Llama AI models, acting as the class representative due to exclusive commercial rights granted by authors.
Light therapy is used to treat cases of neonatal jaundice. Bilirubin, a yellow pigment normally formed in the liver during the breakdown of old red blood cells, cannot always be effectively cleared by a neonate's liver causing neonatal jaundice. Accumulation of excess bilirubin can cause central nervous system damage, and so this buildup of bilirubin must be treated. Phototherapy uses the energy from light to isomerize the bilirubin and consequently transform it into compounds that the newborn can excrete via urine and stools. Bilirubin is most successful absorbing light in the blue region of the visible light spectrum, which falls between 460 and 490 nm. Therefore, light therapy technologies that utilize these blue wavelengths are the most successful at isomerizing bilirubin.
== Background == This dessert originated in France during the 18th century. Among Agnes Blackwell Herrick's papers was a copy of the Paris Embassy's Dinner Party Record from 1921 to 1922. There were 16 different bombes in the collection of recipes, many with geographic names like Alhambra, Muscovite and Cleopatre. It was part of the menu for the wedding of Queen Elizabeth II and Prince Philip. It was served at a White House state dinner hosted by Jacqueline Kennedy Onassis and President Kennedy for the Sudanese president Ibrahim Abboud, and by Queen Elizabeth for Laura and President Bush.
This is based on the absence of Neanderthal mtDNA, as well as the relatively low level of Neanderthal admixture in the modern human X chromosome. According to Svante Pääbo, it is not clear that modern humans were socially dominant over Neanderthals, which may explain why the interbreeding occurred primarily between Neanderthal males and modern human females. A 2026 study confirmed the evidence of sex bias, reporting that sexual selection (i.e., a preference for male Neanderthals and modern human females) was the primary driver of the asymmetric mating patterns, rather than sex biases in demography or migration. Neanderthals in the Siberian Altai Mountains interbred with the local Denisovan population, and it may have been a common occurrence here. About 17% of the genome of one Altai Denisovan specimen derived from Neanderthals. Even before genetic evidence had confirmed this admixture, hybridisation between Neanderthals and early modern humans had been proposed early on, such as by English anthropologist Thomas Huxley in 1890, Danish ethnographer Hans Peder Steensby in 1907, and Coon in 1962. In the early 2000s, supposed hybrid specimens were discovered: Lagar Velho 1 and Muierii 1. These proposals were based on shared anatomy, but modern geneticists have cautioned that some shared anatomy might have been acquired by adaptation to a similar environment, rather than admixture alone.
==== Adaptation to a single environment ==== Given the slow rate of evolution of the genus, Ginkgo possibly represents a pre-angiosperm strategy for survival in disturbed streamside environments. Ginkgo evolved in an era before flowering plants, when ferns, cycads, and cycadeoids dominated disturbed streamside environments, forming low, open, shrubby canopies. Ginkgo's large seeds and habit of "bolting" – growing to a height of 10 meters before elongating its side branches – may be adaptations to such an environment. Modern-day G. biloba grows best in environments that are well-watered and drained, and the extremely similar fossil Ginkgo favored similar environments: The sediment record at the majority of fossil Ginkgo localities indicates it grew primarily in disturbed environments, such as along streams. Ginkgo, therefore, presents an "ecological paradox" because while it possesses some favorable traits for living in disturbed environments (clonal reproduction) many of its other life-history traits are the opposite of those exhibited by modern plants that thrive in disturbed settings (slow growth, large seed size, late reproductive maturity).
Sources: en.wikipedia.org
Engineers have been able to successfully incorporate the AceA and AceB genes into mammalian cells in culture, and the cells were successful in translating and transcribing the genes into the appropriate enzymes, proving that the genes could successfully be incorporated into the cell's DNA without damaging the functionality or health of the cell. However, being able to engineer the pathway into transgenic mice has proven to be difficult for engineers. While the DNA has been expressed in some tissues, including the liver and small intestine in test animals, the level of expression is not high, and not found to be statistically significant. In order to successfully engineer the pathway, engineers would have to fuse the gene with promoters which could be regulated in order to increase the level of expression, and have the expression in the right cells, such as epithelial cells. Efforts to engineer the pathway into more complex animals, such as sheep, have not been effective. This illustrates that much more research needs to be done on the topic, and suggests it is possible that a high expression of the cycle in animals would not be tolerated by the chemistry of the cell. Incorporating the cycle into mammals will benefit from advances in nuclear transfer technology, which will enable engineers to examine and access the pathway for functional integration within the genome before its transfer to animals. There are possible benefits, however, to the cycle's absence in mammalian cells.
Filled French Toast Bacon Cheddar Breakfast Sandwich Pepperoni Pocket Sandwich Jalapeño Cheese Spread Wheat Snack Bread Dessert Bar, Peanut Butter First Strike Bar (HOOAH! Bar) Beef Snack, Teriyaki Beef Snack, BBQ Snack, Pretzels Zapplesauce, Cinnamon Nut Fruit Mix, Type III Chocolate Protein Drink Mix Beverage Base Powder Caffeine Gum Accessory Package
== Major families == The barrier for a regular protein to become a selenoprotein is relatively high due to the requirement for a SECIS element. As a result, new selenoprotein families do not easily appear. It is also not uncommon for these families to include non-selenoprotein descendants, as (mainly terristial) selenium-poor environments provide a fitness advantage to an organism that has lower requirements of selenium. The below will focus on families found in humans.
The 23S rRNA is a 2,904 nucleotide long (in E. coli) component of the large subunit (50S) of the bacterial/archean ribosome and makes up the peptidyl transferase center (PTC). The 23S rRNA is divided into six secondary structural domains titled I-VI, with the corresponding 5S rRNA being considered domain VII. The ribosomal peptidyl transferase activity resides in domain V of this rRNA, which is also the most common binding site for antibiotics that inhibit translation, making it a target for ribosomal engineering. A well-known member of this antibiotic class, chloramphenicol, acts by inhibiting peptide bond formation, with recent 3D-structural studies showing two different binding sites depending on the species of ribosome. Numerous mutations in domains of the 23S rRNA with Peptidyl transferase activity have resulted in antibiotic resistance. 23S rRNA genes typically have higher sequence variations, including insertions and/or deletions, compared to other rRNAs. The eukaryotic homolog of the 23S LSU rRNA is the 28S ribosomal RNA, with a region filled by the 5.8S ribosomal RNA.
=== 21st century === Heather C. Allen, American chemist whose research focuses air-liquid interfaces Rommie Amaro, American chemist focusing on development of computational methods in biophysics for applications to drug discovery. Emily Balskus, American organic and biological chemist, and microbiologist. Recipient of the 2020 Alan T. Waterman Award for her work on understanding the chemistry of metabolic processes. Professor at Harvard University. Natalie Banerji, Swiss chemist and Professor of Chemistry at the University of Bern who studies organic and hybrid materials using ultrafast spectroscopies. Margaret Brimble, New Zealand chemist whose research has included investigations of shellfish toxins and means to treat brain injuries. Jane P. Chang, chemical engineer, materials scientist and professor at UCLA known for her research developing advanced atomic layer deposition (ALD) and etching techniques with applications in microelectronics and energy storage devices. Sherry Chemler, American Organic Chemist. Professor University at Buffalo. ACS Cope Scholar Award recipient (2017). Paulette Clancy, British chemist focusing on computational and machine learning methods, particularly chemistry-informed Bayesian optimization, to model the behavior of semiconductor materials. Sheila Hobbs DeWitt, American chemist. Chair, President, CEO, Cofounder of DeuteRx which has developed PXL065 a Deuterated drug. ACS Kathryn C. Hach Award for Entrepreneurial Success (2025). She is a pioneer of Combinatorial Chemistry.
Sources: en.wikipedia.org
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.
Intranasal delivery is the route described in most published work. It is used because the peptide is degraded quickly once it reaches circulation. Direct evidence of brain penetration in humans is lacking.
Most trials are small, regionally concentrated, and often lack rigorous blinding or placebo control. Independent replication is limited. Reviews in English generally rate the evidence as preliminary.
Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.